TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9398956

Group type: EXPERIMENTAL
Intervention: Dolasetron 100 mg
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Dolasetron 200 mg
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 8199107

Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lenses (3M design)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Monofocal intraocular lenses (all polymethylmethacrylate biconvex, 6 mm optical diameter)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dynamic visual acuity
Number of subjects: 33
Study: 3296260

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with irradiation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 80
Study: 31639232

Group type: EXPERIMENTAL
Intervention: Eating disorder symptoms (high severity, SCOFF score of 5)
Number of subjects: 71712

Group type: EXPERIMENTAL
Intervention: Eating disorder symptoms (subthreshold levels)
Number of subjects: 71712

Group type: EXPERIMENTAL
Intervention: Eating disorder presentations that included purging
Number of subjects: 71712

Group type: EXPERIMENTAL
Intervention: Marginalized backgrounds (gender and sexual minorities)
Number of subjects: 71712
Study: 29466268

Group type: EXPERIMENTAL
Intervention: Progressive calisthenic push-up training (PUSH)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Traditional bench press training (BENCH)
Number of subjects: 23
Study: 27910037

Group type: EXPERIMENTAL
Intervention: Activated Charcoal (AC) administered at 2 hours post-dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Activated Charcoal (AC) administered at 5 hours post-dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Activated Charcoal (AC) administered at 8 hours post-dose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rivaroxaban administered alone
Number of subjects: 12
Study: 25073037

Group type: EXPERIMENTAL
Intervention: Monitoring group (real-time monitoring for HHV-6 and HHV-7 viremia)
Number of subjects: 129

Group type: COMPARATOR
Intervention: No-monitoring group (usual care)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Monitoring group
Number of subjects: 129
Study: 22260882

Group type: EXPERIMENTAL
Intervention: Technology-based cooperative learning
Number of subjects: 98

Group type: COMPARATOR
Intervention: Technology-based individual learning
Number of subjects: 98
Study: 21244568

Group type: EXPERIMENTAL
Intervention: GlideScope(®) videolaryngoscopy (GV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 80
Study: 18458145

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study: 16504078

Group type: EXPERIMENTAL
Intervention: Distraction manipulation (DM) and neural mobilization (NM)
Number of subjects: 55
Study: 14660270

Group type: EXPERIMENTAL
Intervention: Etanercept therapy
Number of subjects: 0
Study: 10856099

Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific dosage and duration not mentioned)
Number of subjects: 300
Study: 9357487

Group type: EXPERIMENTAL
Intervention: Mycodot test for tuberculosis
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mycodot test for tuberculosis in HIV-negative patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mycodot test for tuberculosis in HIV-positive patients
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control sera from patients with acute non-tuberculous lobar pneumonia
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control sera from patients with no respiratory disease
Number of subjects: 52
Study: 31816352

Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with water-insoluble radiolabel (technetium-99 m-labeled ion exchange resin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid) without water ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs) with water-soluble radiolabel (111Indium-diethylenetriaminepentaacetic acid) with water ingestion
Number of subjects: 0
Study: 29422021

Group type: EXPERIMENTAL
Intervention: Decision-theoretic value of information (VOI) method for optimal sample size and significance level in RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision-theoretic VOI methods
Number of subjects: 0
Study: 27568219

Group type: EXPERIMENTAL
Intervention: Double-layer reconstruction
Number of subjects: 58

Group type: COMPARATOR
Intervention: Single-layer reconstruction
Number of subjects: 58
Study: 24425854

Group type: EXPERIMENTAL
Intervention: Daily irrigation with sterile saline solution during silicone hydrogel contact lens continuous wear.
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (no irrigation).
Number of subjects: 161
Study: 23218158

Group type: EXPERIMENTAL
Intervention: Adjunctive oral ziprasidone
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group (lithium or divalproex)
Number of subjects: 504
Study: 19769420

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study: 16792536

Group type: EXPERIMENTAL
Intervention: peginterferon-alpha-2a (40 kDa) plus ribavirin
Number of subjects: 64
Study: 15321956

Group type: EXPERIMENTAL
Intervention: Prophylactic nCPAP
Number of subjects: 230

Group type: COMPARATOR
Intervention: Rescue nCPAP
Number of subjects: 230
Study: 11420326

Group type: EXPERIMENTAL
Intervention: Foot length based estimates
Number of subjects: 59

Group type: COMPARATOR
Intervention: Body weight based estimates
Number of subjects: 59
Study: 9226055

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 400 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 100 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 200 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 800 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 100 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 200 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 400 micrograms
Number of subjects: 0
Study: 8387071

Group type: EXPERIMENTAL
Intervention: 9 mg/kg caffeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (9 mg/kg dextrose)
Number of subjects: 16
Study: 3680589

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.050 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.075 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam 0.100 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (various doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam
Number of subjects: 10
Study: 30002707

Group type: EXPERIMENTAL
Intervention: Median nerve neural mobilization (MNNM)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oral ibuprofen (OI) 1200 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cervical rotation range of motion (CROM)
Number of subjects: 62
Study: 28381812

Group type: EXPERIMENTAL
Intervention: Theaflavin-containing fermentation water
Number of subjects: 2

Group type: COMPARATOR
Intervention: Water without theaflavin
Number of subjects: 2
Study: 26637079

Group type: EXPERIMENTAL
Intervention: High-alarm framing
Number of subjects: 131

Group type: COMPARATOR
Intervention: Low-alarm framing
Number of subjects: 131
Study: 23763455

Group type: EXPERIMENTAL
Intervention: MSC
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 19933744

Group type: EXPERIMENTAL
Intervention: Abatacept (approximately 10 mg/kg) for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 50

Group type: COMPARATOR
Intervention: Abatacept and Placebo
Number of subjects: 50
Study: 18949179

Group type: EXPERIMENTAL
Intervention: captopril 100 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: captopril 50 mg/kg/day (in rats)
Number of subjects: 15
Study: 16981922

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation lesions resulting in bubble formation (327 lesions)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Radiofrequency generator power settings during lesions resulting in bubble formation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Generator temperature settings during RF ablation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Lesions associated with bubble formation occurring within 2-10 seconds after RF was begun
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bubble formation frequency in different pulmonary veins
Number of subjects: 46
Study: 12632438

Group type: EXPERIMENTAL
Intervention: 400 mg/day of oral tiludronate for 3 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 31
Study: 11154142

Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol (2 mg daily) for 8 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9329065

Group type: EXPERIMENTAL
Intervention: 12 oz unsweetened coffee
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 24 oz sugar-free cola
Number of subjects: 13

Group type: COMPARATOR
Intervention: 2 capsules
Number of subjects: 13
Study: 8224679

Group type: COMPARATOR
Intervention: Epinephrine injection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Epinephrine injection followed by 3% sodium tetradecyl sulfate
Number of subjects: 200
Study: 2844333

Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 29594819

Group type: EXPERIMENTAL
Intervention: Serum IL-16 levels
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Serum IL-16 levels among Caucasian men with a history of gonorrhea
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Serum IL-16 levels among Caucasian men without a history of gonorrhea
Number of subjects: 932

Group type: COMPARATOR
Intervention: Serum IL-16 levels among African-Americans
Number of subjects: 932
Study: 28232949

Group type: EXPERIMENTAL
Intervention: ELKa system (n = 53)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Conventional calculation methods (n = 53)
Number of subjects: 106
Study: 25278139

Group type: COMPARATOR
Intervention: Dexamethasone/Metoclopramide
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Number of subjects: 70
Study: 23306407

Group type: EXPERIMENTAL
Intervention: Bubble CPAP (BCPAP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ventilator-derived CPAP (VCPAP)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Failure of CPAP (both groups)
Number of subjects: 114
Study: 21815126

Group type: EXPERIMENTAL
Intervention: Stretching (low-intensity exercise)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Walking (moderate-intensity exercise)
Number of subjects: 11
Study: 18822172

Group type: EXPERIMENTAL
Intervention: Trial chemotherapy and FLC removal haemodialysis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Trial chemotherapy and standard high flux haemodialysis
Number of subjects: 90
Study: 16445787

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15357564

Group type: EXPERIMENTAL
Intervention: SAM and S. boulardii
Number of subjects: 466

Group type: COMPARATOR
Intervention: SAM alone
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: AZT and S. boulardii
Number of subjects: 466

Group type: COMPARATOR
Intervention: AZT alone
Number of subjects: 466
Study: 12241628

Group type: EXPERIMENTAL
Intervention: 1% colchicine cream applied twice daily for 10 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.5% colchicine cream applied twice daily for 10 days
Number of subjects: 16
Study: 9277046

Group type: EXPERIMENTAL
Intervention: Iron supplementation (66 mg ferrous iron daily from second trimester until delivery)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 8341890

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg diphenhydramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ethanol placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 12
Study: 3566241

Group type: EXPERIMENTAL
Intervention: 1 g of intramuscular ceftriaxone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5 g of intramuscular ceftriaxone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.25 g of intramuscular ceftriaxone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 250 mg of intramuscular ceftriaxone
Number of subjects: 50
Study: 31724489

Group type: EXPERIMENTAL
Intervention: Isolated hypothyroxinemia
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Subclinical hypothyroidism
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Pregnant women over 30 years old
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Second and third trimesters
Number of subjects: 1080

Group type: COMPARATOR
Intervention: History of multiparity
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Residing in rural areas
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Residing in the capital province
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Thyroid peroxidase positive pregnant women
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Urinary iodine concentration (UIC)
Number of subjects: 1080
Study: 27704628

Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance training (PRT) during radiotherapy
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 146
Study: 25903742

Group type: EXPERIMENTAL
Intervention: Nefopam (160 mg in 200 ml at a rate of 4 ml/h)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 98
Study: 23868708

Group type: EXPERIMENTAL
Intervention: School-based intervention program (n=94)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (n=85)
Number of subjects: 179
Study: 21357827

Group type: EXPERIMENTAL
Intervention: Dual therapy (telmisartan and ramipril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin receptor blocker (telmisartan)
Number of subjects: 0
Study: 20037682

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 17944340

Group type: EXPERIMENTAL
Intervention: Titanium post
Number of subjects: 91

Group type: COMPARATOR
Intervention: Glass fiber post
Number of subjects: 91
Study: 14982495

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient involvement in trial design
Number of subjects: 0
Study: 11237275

Group type: EXPERIMENTAL
Intervention: Stimulation Group (SG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 42
Study: 9509952

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) measurement
Number of subjects: 51

Group type: COMPARATOR
Intervention: Body temperature (BT), erythrocyte sedimentation rate (ESR), and serum leukocyte concentration (L)
Number of subjects: 51
Study: 7995154

Group type: EXPERIMENTAL
Intervention: Interferon alfa-n3 (500,000 IU, 0.1 ml) injected into each quadrant of the anal canal after surgical excision and fulguration
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline (0.1 ml) injected into each quadrant of the anal canal after surgical excision and fulguration
Number of subjects: 43
Study: 3050686

Group type: EXPERIMENTAL
Intervention: ALO 2145 (1.0% para‐amino‐clonidine)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 165
Study: 31571351

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet with dietitian guidance
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low FODMAP diet without dietitian guidance
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Number of subjects: 80
Study: 31623349

Group type: EXPERIMENTAL
Intervention: RC supplementation (20 mg/kg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Endurance training (both groups)
Number of subjects: 14
Study: 28838395

Group type: EXPERIMENTAL
Intervention: Carboplatin plus irinotecan (CI)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Carboplatin plus amrubicin (CA)
Number of subjects: 71
Study: 26165918

Group type: EXPERIMENTAL
Intervention: Tdap-IPV (low-dose diphtheria, tetanus, acellular pertussis and inactivated polio vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tdap + OPV (low-dose diphtheria, tetanus, acellular pertussis vaccine with oral polio vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTap-IPV (standard-dose diphtheria, tetanus, acellular pertussis and inactivated polio vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (Tdap-IPV, Tdap + OPV, DTap-IPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tdap + OPV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose diphtheria vaccines
Number of subjects: 0
Study: 23230900

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-stretching (control condition)
Number of subjects: 49
Study: 21709065

Group type: EXPERIMENTAL
Intervention: Ticagrelor with low-dose maintenance aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel with low-dose maintenance aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 18413218

Group type: EXPERIMENTAL
Intervention: Diabetic subjects (n=983)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Diabetic women (n=438)
Number of subjects: 983

Group type: COMPARATOR
Intervention: Diabetic subjects in the DCCT intensive treatment group (n=479)
Number of subjects: 983
Study: 17243593

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (AP)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (S3)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: G-Bond (GB)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: iBond (iB)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Xeno IV (XE)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Adper Single Bond Plus (SB)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Clearfil SE Bond (SE)
Number of subjects: 84
Study: 14694028

Group type: EXPERIMENTAL
Intervention: Down syndrome (DS) group
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moderate Alzheimer's disease (AD) group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 10963840

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 9100165

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dermatan sulphate (Desmin) administered at doses of 400 mg (intravenous bolus) followed by 1200 mg/day infused intravenously for 10 days
Number of subjects: 10
Study: 8227937

Group type: EXPERIMENTAL
Intervention: Spray to eyes that were closed
Number of subjects: 38

Group type: COMPARATOR
Intervention: Eyedrops to eyes that were open
Number of subjects: 38

Group type: COMPARATOR
Intervention: Eyedrops to eyes that were closed
Number of subjects: 38

Group type: COMPARATOR
Intervention: Spray to eyes that were open
Number of subjects: 38
Study: 6141187

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31409981

Group type: EXPERIMENTAL
Intervention: PCV-VG
Number of subjects: 76

Group type: COMPARATOR
Intervention: VCV
Number of subjects: 76
Study: 29205080

Group type: EXPERIMENTAL
Intervention: Respiratory Gating (RG) for left-sided patients
Number of subjects: 1327

Group type: COMPARATOR
Intervention: Free-Breathing (FB) for left-sided patients
Number of subjects: 1327

Group type: COMPARATOR
Intervention: Free-Breathing (FB) for right-sided patients
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: Normofractionated therapy
Number of subjects: 1327

Group type: EXPERIMENTAL
Intervention: Hypofractionated therapy
Number of subjects: 1327
Study: 26936782

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 14
Study: 25157929

Group type: EXPERIMENTAL
Intervention: Intervention group (Total Sanitation Campaign)
Number of subjects: 5209

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5209
Study: 20828304

Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine
Number of subjects: 385
Study: 15576836

Group type: EXPERIMENTAL
Intervention: 2.8 g of phosphatidylinositol (PI) with food
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5.6 g of phosphatidylinositol (PI) with food
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2.8 g and 5.6 g of phosphatidylinositol (PI)
Number of subjects: 16